Literature DB >> 24238124

Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile?

Masaru Miyazaki1, Hideyuki Yoshitomi2, Hiroaki Shimizu2, Masayuki Ohtsuka2, Hiroyuki Yoshidome2, Katsunori Furukawa2, Tsukasa Takayasiki2, Satoshi Kuboki2, Daiki Okamura2, Daisuke Suzuki2, Masayuki Nakajima2.   

Abstract

BACKGROUND: The clinical implications of repeat completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas after initial pancreatectomy have not been clarified. We retrospectively analyzed our patients and evaluated the clinical implications of repeat pancreatectomy for isolated local recurrence in the remnant pancreas after initial resection for pancreatic cancer.
METHODS: One-hundred seventy patients who had recurrence of pancreatic cancer out of 326 patients who had initially undergone resection for pancreatic cancer were included in this study. Sixty-seven of 170 recurrent patients were diagnosed as having isolated local recurrence of pancreatic cancer. Eleven of these 67 patients with isolated local recurrence only in the remnant pancreas underwent repeat pancreatectomy. Characteristics and operative outcomes for these 11 patients with repeat pancreatectomy were analyzed and evaluated in comparison with other recurrent patients.
RESULTS: Among 170 patients with recurrence after initial resection for pancreatic cancer, the median survival time was 78.2 and 20.3 months after initial resection, in the repeat pancreatectomy group and the unresectable group, respectively (P < .001), and the 2- and 5-year survival probability rates after initial resection were 91%, and 82% vs 42%, and 13%, respectively. Among 67 patients with isolated local recurrence, the median survival time after repeat resection or diagnosis of recurrence was 25.0 and 9.3 months, and the 2- and 5-year survival probability rates after repeat resection or diagnosis of recurrence were and 61% and 46% vs 19% and 6.2% in the repeat pancreatectomy group and the unresectable group, respectively (P < .01). There was no difference in survivals between the unresectable isolated local recurrence group and the unresectable nonlocal recurrence group.
CONCLUSION: Repeat pancreatectomy might bring about beneficial effects on prognosis in selected patients with isolated local recurrence in the remnant pancreas after initial pancreatectomy for pancreatic cancer without increased operative morbidity or mortality.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24238124     DOI: 10.1016/j.surg.2013.06.050

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  29 in total

1.  Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Authors:  Daisuke Hashimoto; Kota Arima; Shigeki Nakagawa; Yuji Negoro; Toshihiko Hirata; Masahiko Hirota; Masafumi Inomata; Kengo Fukuzawa; Takefumi Ohga; Hiroshi Saeki; Eiji Oki; Yo-Ichi Yamashita; Akira Chikamoto; Hideo Baba; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2018-12-04       Impact factor: 7.527

2.  The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.

Authors:  Woohyun Jung; Jin-Young Jang; Mee Joo Kang; Ye Rim Chang; Yong Chan Shin; Jihoon Chang; Sun-Whe Kim
Journal:  HPB (Oxford)       Date:  2015-12-21       Impact factor: 3.647

3.  Multimodality treatment of recurrent pancreatic cancer: Mith or reality?

Authors:  Cosimo Sperti; Lucia Moletta; Stefano Merigliano
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

Review 4.  Resection of Recurrent Pancreatic Cancer: Who Can Benefit?

Authors:  Henrik Nienhüser; Markus W Büchler; Martin Schneider
Journal:  Visc Med       Date:  2021-11-11

5.  Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection.

Authors:  Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang
Journal:  J Gastrointest Oncol       Date:  2022-06

Review 6.  Minimally invasive surgery for pancreatic cancer.

Authors:  Yoshihiro Miyasaka; Takao Ohtsuka; Masafumi Nakamura
Journal:  Surg Today       Date:  2020-08-28       Impact factor: 2.549

Review 7.  Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature.

Authors:  Yasuo Shima; Takehiro Okabayashi; Akihito Kozuki; Tatsuaki Sumiyoshi; Teppei Tokumaru; Yuichi Saisaka; Keiichi Date; Jun Iwata
Journal:  Langenbecks Arch Surg       Date:  2015-11-06       Impact factor: 3.445

8.  Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress.

Authors:  Xia Jiang; Tatsuo Kanda; Shingo Nakamoto; Yuki Haga; Reina Sasaki; Masato Nakamura; Shuang Wu; Rintaro Mikata; Osamu Yokosuka
Journal:  Oncol Rep       Date:  2014-10-06       Impact factor: 3.906

9.  Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.

Authors:  John B Hamner; Michael White; Carly Crowder; Gagandeep Singh
Journal:  World J Surg Oncol       Date:  2015-09-30       Impact factor: 2.754

10.  Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs).

Authors:  Koji Imai; Hidenori Karasaki; Yusuke Ono; Junpei Sasajima; Shin-Ichi Chiba; Hiroshi Funakoshi; Miho Muraki; Hideki Hanaoka; Takahisa Furukawa; Hiroyuki Furukawa; Toru Kono; Kazuo Nagashima; Yusuke Mizukami
Journal:  J Pathol Clin Res       Date:  2015-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.